These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35095082)

  • 21. Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.
    Matsumura K; Morishita S; Taniguchi N; Takehana K; Takahashi H; Otagaki M; Yoshioka K; Yamamoto Y; Takagi M; Shiojima I
    Heart Vessels; 2019 Apr; 34(4):607-615. PubMed ID: 30386917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
    Iida Y; Yoshitake A; Shimizu H
    Ann Vasc Surg; 2019 Apr; 56():103-107. PubMed ID: 30342208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
    Takimura H; Hada T; Kawano M; Yabe T; Takimura Y; Nishio S; Nakano M; Tsukahara R; Muramatsu T
    PLoS One; 2018; 13(11):e0207481. PubMed ID: 30427915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T; Kinugawa K; Komuro I
    Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
    Kajimoto K; Otsubo S
    Am J Case Rep; 2019 Jul; 20():1006-1010. PubMed ID: 31296836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
    Takimura H; Kurozumi A; Taniguchi R; Tsuzuki I; Tajima E; Yamaguchi Y; Kawano M; Takimura Y; Nishio S; Nakano M; Tsukahara R
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):185-196. PubMed ID: 36739357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R
    Circ J; 2013; 77(2):397-404. PubMed ID: 23131721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan.
    Nakao Y; Kawakami H; Saito M; Inoue K; Ikeda S; Yamaguchi O
    J Cardiol; 2022 Mar; 79(3):408-416. PubMed ID: 34799217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
    Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure.
    Yamashita S; Takenaka M; Ohbayashi M; Kohyama N; Kurihara T; Sunaga T; Ishiguro H; Kogo M
    Singapore Med J; 2023 Feb; ():. PubMed ID: 36751847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Murakami Y; Sano T; Ikeda T
    BMC Cardiovasc Disord; 2022 Apr; 22(1):202. PubMed ID: 35488212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
    Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
    Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolvaptan can improve clinical course in responders.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2013; 54(6):377-81. PubMed ID: 24309447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure.
    Zhang ZG; Liu XM
    Medicine (Baltimore); 2018 Jan; 97(1):e8706. PubMed ID: 29505505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality.
    Imamura T; Kinugawa K; Kato N; Minatsuki S; Muraoka H; Inaba T; Maki H; Shiga T; Hatano M; Hosoya Y; Takahashi M; Yao A; Kyo S; Ono M; Komuro I
    Int Heart J; 2013; 54(2):115-8. PubMed ID: 23676373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y
    Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.